Risk of myocardial ischaemia and beta-adrenoceptor agonists

References

• Freidman M, Woodcock J, Lumpkin M, Shuren J, Hass S, Thompson L. The safety of newly approved medicines: do recent market removals mean there is a problem. JAMA 1999; 281: 1728–34
   PubMedGoogle Scholar
• Smalley W, Shatin D, Wysowski D K, Gurwitz J, Andrade S E, Goodman M, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284: 3036–9
   PubMed Web of Science ®Google Scholar
• Moore T J, Psaty B M, Furberg C D. Time to act on drug safety. JAMA 1998; 279: 1571–3
   PubMed Web of Science ®Google Scholar
• Neville E, Corris P, Vivian J, Nariman S, Gibson G. Nebulised salbutamol and angina. BMJ 1982; 285: 796–7
   PubMedGoogle Scholar
• Inman W H, Adelstein A M. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 2: 279–85
   PubMed Web of Science ®Google Scholar
• Lockett M. Dangerous effects of isoprenaline in myocardial failure. Lancet 1963; 2: 104–6
   Google Scholar
• Crane J, Flatt A, Jackson R, Ball M, Pearce N, Burgess C, et al. Prescribed fenoterol and death form asthma in New Zealand, 1981–83: case-control study. Lancet 1989; i: 917–22
   Google Scholar
• Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al. Prescribed fenoterol and death form asthma in Newzealand, 1981–7: a further case-control study. Thorax 1991; 46: 105–11
   PubMed Web of Science ®Google Scholar
• Ernst P, Habbick B, Suissa S, Hemmelgarn B, Cockcroft D, Buist A, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity. Am Rev Respir Dis 1993; 148: 75–9
   PubMed Web of Science ®Google Scholar
• Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977–81. Thorax 1990; 45: 170–5
   PubMed Web of Science ®Google Scholar
• Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995; 345: 41–4
   PubMed Web of Science ®Google Scholar
• Spitzer W, Suissa S, Ernst P, Horwitz R, Habbick B, Cockcroft D, et al. The use of B-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501–6
   PubMed Web of Science ®Google Scholar
• Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7
   PubMed Web of Science ®Google Scholar
• A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707–14
   PubMed Web of Science ®Google Scholar
• Lulich K, Goldie R, Ryan G, Paterson J. Adverse reactions to B2-agonist bronchodilators. Med Toxicol 1986; 1: 286–99
   PubMedGoogle Scholar
• Wong C, Pavord I, Williams J, Britton J, Tattersfield A. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396–9
   PubMed Web of Science ®Google Scholar
• Cazzola M, Imperatore F, Salzillo A, Perna F D, Calderaro F, Imperatore A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114: 411–5
   PubMed Web of Science ®Google Scholar
• Robin E, McCauley R. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. Chest 1992; 101: 1699–702
   PubMed Web of Science ®Google Scholar
• Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154: 1598–602
   PubMed Web of Science ®Google Scholar
• Martin R, Dunn N, Freemantle S, Mann R. Risk of non-fatal cardiac failure and ischaemic heart disease with long 27. acting beta-2 agonists. Thorax 1998; 53: 558–62
   PubMedGoogle Scholar
• Au D, Lemaitre R, Curtis J, Smith N, Psaty B. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000; 161: 827–30
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Mak J, Shirasaki H, Barnes P. Differential down-regulation of pulmonary E1- and B2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline. Eur J Pharmacol 1993; 247: 131–8
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Mak J, Barnes P. Effect of short and long-acting B2-adrenoceptor agonists on pulmonary B2-adrenoceptor expression in human lung. Eur J Pharmacol 1996; 318: 123–9
   PubMed Web of Science ®Google Scholar
• Nogami M, Romberger D, Rennard S, Toews M. Agonist-induced desensitation fo B-adrenoceptors of bovine bronchial epithelial cells. Clin Sci 1993; 85: 651–7
   Google Scholar
• Bengtsson B, Fagerstrom P. Extrapulmonary effect of terbutaline during prolonged administration. Clin Phamacol Ther 1982; 31: 726–32
   PubMedGoogle Scholar
• Bengtsson B. Extrapulmonary effect of terbutaline. Eur J Respir Dis 1984; 65((Suppl 134))231–5
   Google Scholar
• Psaty B, Koepsell T, Wagner E, LoGerfo J, Inui T. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263: 1653–7
   PubMed Web of Science ®Google Scholar
• Hall I P. Beta 2 adrenoceptor polymorphisms: are they clinically important. Thorax 1996; 51: 351–3
   PubMedGoogle Scholar
• Green S A, Turki J, Bejarano P, Hall I P, Liggett S B. Influence of [beta]2-adrenergic receptor genotypes on signal trans-duction in human airways smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13: 25–33
   PubMed Web of Science ®Google Scholar
• Tan S, Hall I P, Dewar J, Dow E, Lipworth B. Association between [beta]2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmaties. Lancet 1997; 350: 995–9
   PubMed Web of Science ®Google Scholar